Gregg Gilbert
Stock Analyst at Truist Securities
(2.24)
# 2,755
Out of 5,131 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $13.42 | +26.68% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $45.54 | -18.75% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $55.86 | +50.38% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $1,063.56 | -50.64% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $5.65 | +130.09% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $14.35 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $110.53 | -15.86% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $28.22 | +70.09% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.69 | +1,438.46% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.64 | +23,202.78% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $15.08 | +417.24% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $127.17 | -38.66% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $32.01 | -43.77% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $206.54 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $161.13 | +8.61% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $220.08 | -70.01% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $13.42
Upside: +26.68%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $45.54
Upside: -18.75%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $55.86
Upside: +50.38%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $1,063.56
Upside: -50.64%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $5.65
Upside: +130.09%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $14.35
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $110.53
Upside: -15.86%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $28.22
Upside: +70.09%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.69
Upside: +1,438.46%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.64
Upside: +23,202.78%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $15.08
Upside: +417.24%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $127.17
Upside: -38.66%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $32.01
Upside: -43.77%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $206.54
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $161.13
Upside: +8.61%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $220.08
Upside: -70.01%